Literature DB >> 29021100

The value of endomyocardial biopsy in diagnosis and guiding therapy.

Tayyaba Khan1, Dinesh Selvakumar2, Siddharth Trivedi2, Karan Rao2, Mehmet Harapoz2, Aravinda Thiagalingam3, A Robert Denniss3, Winny Varikatt4.   

Abstract

Endomyocardial biopsy (EMB) is a highly-specialised procedure that is associated with some controversy as to its diagnostic role due to its inconsistency in diagnosing a wide variety of cardiac diseases. Given the advances and sophistication in echocardiography and cardiac magnetic resonance imaging (MRI), the vast majority of cardiac diseases can be diagnosed by these non-invasive procedures. Under-sampling and the fact that biopsy site is limited to the right side of the interventricular septum further limits its value. In spite of all these limitations, there still remains a group of pathological conditions that require biopsy for a conclusive diagnosis such as myocarditis, amyloidosis, sarcoidosis and giant cell myocarditis. Correct patient selection and the quantity of tissue samples impart a significant influence on the accuracy of the diagnosis, and thus the value of EMB is variable for each patient. The purpose of this study was to evaluate the role of EMB in patient care, through its ability to either change clinical diagnosis or alter patient management. Our study was based in a single teaching centre. An audit of cardiac biopsies performed over a 10 year period identified 250 patients. We assessed indications, histology, electron microscopic findings, final clinical diagnosis and how they influenced patient management. A definite diagnosis on histology was given in 44 of 250 patients (17.6%). Non-specific findings were observed in the remaining 206 patients (82.4%). Histology influenced patient management in 73 (29.2%) patients. Histological examination in the remaining 177 biopsies (70.8%) did not provide a definite diagnosis or influence patient management. It was additionally found that the number of tissue fragments sampled has significant impact on diagnostic accuracy. A more accurate diagnosis of 45% was obtained when ≥5 fragments were sampled, as compared to 1-3 fragments where accuracy dropped to 20%. Our study indicated that sampling for electron microscopy has very limited value. We found that of 245 biopsies sampled for electron microscopy, only three biopsies (1.2%) had diagnostically useful findings. In our institution procedure related complications were observed in 7 of 250 patients (2.8%). The diagnostic value of EMB is important but limited. Strict triaging of patients according to clinical suspicion and adequate sampling of tissue may increase useful diagnostic information. Crown
Copyright © 2017. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Endomyocardial biopsy; cardiac amyloidosis; diagnostic value; electron microscope

Mesh:

Year:  2017        PMID: 29021100     DOI: 10.1016/j.pathol.2017.08.004

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  9 in total

Review 1.  Imaging tools for assessment of myocardial fibrosis in humans: the need for greater detail.

Authors:  Summer Hassan; Carolyn J Barrett; David J Crossman
Journal:  Biophys Rev       Date:  2020-07-23

2.  Technetium-99m pyrophosphate cardiac SPECT in endomyocardial biopsy negative cardiac amyloidosis.

Authors:  Martin Krupa; Rina Nguyen; Jonathan Revels; Lester S Johnson
Journal:  Radiol Case Rep       Date:  2018-07-19

3.  Implications of multiple late gadolinium enhancement lesions on the frequency of left ventricular reverse remodeling and prognosis in patients with non-ischemic cardiomyopathy.

Authors:  Shingo Ota; Makoto Orii; Tsuyoshi Nishiguchi; Mao Yokoyama; Ryoko Matsushita; Kazushi Takemoto; Takashi Tanimoto; Kumiko Hirata; Takeshi Hozumi; Takashi Akasaka
Journal:  J Cardiovasc Magn Reson       Date:  2021-03-25       Impact factor: 5.364

Review 4.  Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).

Authors:  A Yilmaz; J Bauersachs; F Bengel; R Büchel; I Kindermann; K Klingel; F Knebel; B Meder; C Morbach; E Nagel; E Schulze-Bahr; F Aus dem Siepen; N Frey
Journal:  Clin Res Cardiol       Date:  2021-01-18       Impact factor: 5.460

5.  Evaluation of cardiomyopathy diagnosis in heart transplant recipients: comparison of echocardiographic and pathologic classification.

Authors:  Neda Behzadnia; Babak Sharif-Kashani; Zargham Hossein Ahmadi; Farah Naghashzadeh; Atosa Dorudinia; Alireza Jahangirifard; Hamoun Hamarz; Payam Abbasi
Journal:  Egypt Heart J       Date:  2021-03-25

6.  Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis.

Authors:  Angela Pucci; Alberto Aimo; Veronica Musetti; Andrea Barison; Giuseppe Vergaro; Dario Genovesi; Assuero Giorgetti; Silvia Masotti; Chiara Arzilli; Concetta Prontera; Luigi Emilio Pastormerlo; Michele Alessandro Coceani; Marco Ciardetti; Nicola Martini; Cataldo Palmieri; Claudio Passino; Claudio Rapezzi; Michele Emdin
Journal:  J Am Heart Assoc       Date:  2021-10-08       Impact factor: 5.501

7.  Safety evaluation of high-risk myocardial micro-biopsy in a swine model.

Authors:  Arvin Chireh; Mikael Sandell; Rikard Grankvist; Victoria Lövljung; Jonathan Al-Saadi; Fabian Arnberg; Johan Lundberg; Magnus Settergren; Staffan Holmin
Journal:  Heart Vessels       Date:  2021-11-23       Impact factor: 2.037

8.  3.0T cardiac magnetic resonance quantification of native T1 and myocardial extracellular volume for the diagnosis of late gadolinium enhancement-negative cardiac amyloidosis.

Authors:  Yumeng Liu; Jingfen Zhu; Meng Chen; Lingjie Wang; Mo Zhu; Zhen Weng; Chunhong Hu
Journal:  Ann Transl Med       Date:  2022-07

Review 9.  A Comprehensive Review of Sarcoidosis Diagnosis and Monitoring for the Pulmonologist.

Authors:  Andrea S Melani; Albano Simona; Martina Armati; Miriana d'Alessandro; Elena Bargagli
Journal:  Pulm Ther       Date:  2021-06-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.